Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Galectin Therapeutics Stories

2013-12-02 23:26:33

Galectin Therapeutics, a development-stage company, engages in the discovery and development of therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases, granted an exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV during recent FSXinterlinked Investment Conference. (PRWEB) December 02, 2013 Galectin Therapeutics was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz...

2013-05-30 23:30:44

Galectin Therapeutics granted Interlinked an Exclusive Interview on their leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer during recent FSX Investment Conference (PRWEB) May 30, 2013 At the recent FSX Investment Conference held at the Ritz-Carlton in San Francisco, California, James Czirr, Executive Chairman of Galectin Therapeutics granted an exclusive interview available on Galectin Therapeutics's Public Profile on Interlinked's...

2013-05-23 08:28:46

ATLANTA, May 23, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Due to technological difficulties, a different phone number than previously circulated will be used for accessing the call. The audio portion of the call can now be accessed by dialing (888) 582-3528 (toll-free within the United States) or (847) 944-7361...

2013-05-15 08:30:19

ATLANTA, May 15, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment community on the Company's pipeline of galectin inhibitor compounds and progress in its development of treatments for liver fibrosis and cancer. Following...

2013-04-29 08:27:39

- Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 - NORCROSS, Ga., April 29, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today released data that was presented on April 27, 2013 at the International Liver Congress in Amsterdam, The Netherlands. The data were generated by the laboratory of Dr. Scott...